Keywords: Selumetinib, NSCLC, Targeted therapy, Dana-Farber, Array BioPharma, AstraZeneca,

First success of selumetinib, a targeted therapy in most common NSCLC

Article | 29 November 2012

Print This

A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in